Pulmonary hypertension in pediatrics. A feasible approach to bridge the gap between real world and guidelines

Giuseppe Calcaterra1, Pier Paolo Bassareo2, Francesco Barilla3

  • 1Department of Cardiology, University of Palermo, Palermo, Italy.

Insights

Pediatric pulmonary hypertension (PH) requires simplified classification. A new 5-group method aids clinicians in diagnosing this severe condition, improving patient outcomes.

Area of Science:

  • Pediatric Cardiology
  • Pulmonology
  • Neonatology

Background:

  • Pediatric pulmonary hypertension (PH) is rare but severe, with distinct causes from adults.
  • Existing PH classifications for adults are inadequate for children.
  • Previous pediatric classifications are complex and difficult for clinicians to apply.

Purpose of the Study:

  • To propose a simplified clinical classification for pediatric pulmonary hypertension.
  • To aid clinicians in the initial diagnosis and management of pediatric PH.
  • To improve understanding and recognition of PH in neonates and children.

Main Methods:

  • Review of existing adult and pediatric PH classification systems.
  • Analysis of the unique etiologies of PH in pediatric populations.
  • Development of a simplified 5-group clinical classification based on physician specialty.

Main Results:

  • Existing classifications are complex and not easily understood by clinicians.
  • A new, simplified 5-group classification is proposed: neonatal, cardiac, developmental, idiopathic, and syndromic PH.
  • This simplified approach is intended to assist physicians in initial diagnosis.

Conclusions:

  • Pediatric PH is a serious condition with high morbidity and mortality if untreated.
  • A simplified classification aids clinicians, including neonatologists, pediatric cardiologists, and pulmonologists.
  • The proposed classification complements, rather than replaces, existing systems for better clinical utility.

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
525
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
406
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
529
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
399
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
177
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
500